Dr. Thomas Derlin, LL.M. (Sydney)

Lawyer, Partner*

Practice Areas

  • Commercial contract law
  • Corporate/M&A
  • Private equity & venture capital
Show moreShow less
Education and Professional Experience
  • Lawyer at GSK Stockmann since 2016
  • Worked in three leading international law firms in the fields of corporate/M&A, private equity & venture capital, capital market law and commercial contract law focusing in particular on technology, internet and media companies
  • Admitted to practise law in Germany (2005)
  • Research assistant at the Institute for Commercial Law at the University of Freiburg
  • Doctorate from the University of Freiburg (Dr. jur.)
  • Studies at the University of Freiburg, the University of North Carolina and the University of Sydney (LL.M.)
Languages
  • English, German, Italian
Memberships
  • Alumnus of the Foundation of the German Economy (sdw)
  • Alumnus of the German Academic Exchange Service (DAAD)
Awards
  • Recommended lawyer in the field of “Venture Capital” (The Legal 500 2024)
  • Recommended lawyer in the field of  “Private-Equity-Transactions (Mid-Cap)” and “Venture Capital” (Juve Handbuch 2023/2024)
  • Ranking “Germany’s Best Lawyers” in the areas of “Corporate Law, M&A” (Handelsblatt and Best Lawyers in Germany 2022-2024)
Publications
  • Derlin, Thomas: Leaver Regelungen für Gründer: The „good“, the „bad“ and the „intermediate“, in: Venture Capital Magazin (Start-up 2022), S. 74ff., 02.11.2021.
  • Various publications on Corporate and Commercial Law
Dr. Thomas Derlin, Rechtsanwalt Deal News
06 May 2024

GSK Stockmann advises Unstoppable Finance on the sale of Ultimate Wallet to leading Solana Exchange Jupiter

GSK Stockmann advised the Berlin-based crypto firm Unstoppable Finance GmbH on the takeover of its Ultimate Wallet by Jupiter.

Read more
Dr. Thomas Derlin, Rechtsanwalt Deal News
10 July 2023

GSK Stockmann advised the shareholders of MVPF Technologies GmbH on the sale to Ness Digital Engineering (a KKR Company)

GSK Stockmann has provided the shareholders of MVPF Technologies GmbH, the company behind the Berlin venture builder MVP Factory, with comprehensive advice on the sale of all share...

Read more
Dr. Thomas Derlin, Rechtsanwalt Deal News
28 September 2022

GSK Stockmann advises MVP Match on financing round

GSK Stockmann advised the Berlin-based start-up MVPF Global Talent Solutions GmbH (MVP Match)– also on its most recent financing round.

Read more
Dr. Thomas Derlin, Rechtsanwalt Deal News
24 August 2022

GSK Stockmann advises Unstoppable Finance on Series A funding round

GSK Stockmann has advised Berlin-based Unstoppable Finance GmbH on its latest funding round.

Read more
Deal News
16 August 2022

GSK Stockmann advises Fundament Advisory on joint venture with Edmond de Rothschild REIM

GSK Stockmann has advised Fundament Advisory on a residential real estate investment management joint venture in Germany with Edmond de Rothschild REIM.

Read more
Law firm
24 June 2022

Germany’s Best Lawyers 2022: Handelsblatt and Best Lawyers recommend 53 lawyers from GSK Stockmann

The renowned US publication Best Lawyers has once again published its list of “Germany’s Best Lawyers” of the year in cooperation with Handelsblatt. A total of 53 GSK lawyers...

Read more
19 June 2020

Corona Matching Facility and package of measures for start-ups and SMEs

After a long waiting period, the 2 billion-euro package of measures has now been implemented in both pillars. The measures have been designed to provide financial support for innov...

Read more
09 April 2020

Corporate financing in times of the corona-virus – available government programmes

In order to mitigate the economic consequences of the coronavirus pandemic, various economic and financial policy measures have been announced, initiated and adopted at federal and...

Read more
30 March 2020

Impact of the coronavirus pandemic on contractual relationships

Pacta sunt servanda in times of crisis? We answer legal questions concerning the fulfilment of contractual relationships. Read our GSK update on the coronavirus pandemic now.

Read more